<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02415959</url>
  </required_header>
  <id_info>
    <org_study_id>PANC2002</org_study_id>
    <secondary_id>2014-004519-35</secondary_id>
    <nct_id>NCT02415959</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</brief_title>
  <official_title>A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>LKF Laboratorium für Klinische Forschung GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Analytical Biochemical Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Datamap</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of different doses of Creon
      Immediate Release (IR) in comparison to Creon® 25,000 Delayed Release/Gastro-Resistant
      (DR/GR) in subjects with Pancreatic Exocrine Insufficiency (PEI) due to Cystis Fibrosis (CF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase II, randomized, parallel-group, active-controlled, double-blind, dose
      ranging, multicenter study with 4 different doses of Creon IR and one dose of the active
      control Creon® (DR/GR), administered in subjects of 12 years or older with PEI due to CF.

      The study is divided into two periods: a screening period of 14 days and a double-blind
      treatment period of 6 to 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of Fat Absorption (CFA)</measure>
    <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
    <description>CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coefficient of Nitrogen Absorption (CNA)</measure>
    <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
    <description>CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Fat Content</measure>
    <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
    <description>Total amount of fat excreted during the stool collection period in grams.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Weight</measure>
    <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
    <description>Total amount of stool weight during the collection period in grams</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>From randomization to end of Double Blind period plus 1 day, i.e. up to 7/8 days</time_frame>
    <description>Treatment emergent adverse events will be summarized per treatment group</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Creon IR low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon IR medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon IR high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon IR maximum dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon® (DR/GR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon IR</intervention_name>
    <arm_group_label>Creon IR low dose</arm_group_label>
    <arm_group_label>Creon IR medium dose</arm_group_label>
    <arm_group_label>Creon IR high dose</arm_group_label>
    <arm_group_label>Creon IR maximum dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon® (DR/GR)</intervention_name>
    <arm_group_label>Creon® (DR/GR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has voluntarily signed and dated the Informed Consent Form (ICF). For subjects
             aged less than 18 years, the parents, or a legally acceptable representative, must
             sign consent and, as required by the Independent Ethics Committee (IEC), assent will
             be given by the subject.

          2. Subject is 12 years old or older at the time of consent signature.

          3. Subject has a diagnosis of CF previously confirmed by:

               -  a sweat chloride test &gt; or equal to 60 mmol/Ls and/or

               -  two CF causing Cystic Fibrosis trans membrane conductance regulator (CFTR)
                  mutations and

               -  CF clinical features

          4. Subject has a documented clinically confirmed diagnosis of pancreatic exocrine
             insufficiency.

          5. Subject has human fecal elastase &lt; 100 µg/g stool at screening

          6. Subject has PEI that is currently clinically controlled (no clinically overt
             steatorrhea or diarrhea) under treatment with a commercially available Pancreatic
             enzyme Replacement Therapy (PERT), on an individually established dose regimen for
             more than 3 months, with a daily dose not exceeding 10,000 U lipase/kg/day.

          7. Females of child-bearing potential and sexually active with men should agree to
             continue using a medically acceptable method of birth control throughout the study and
             for 7 days immediately after the last dose of study drug. Medically acceptable methods
             of birth control include bilateral tubal ligation or the use of either a contraceptive
             implant, a contraceptive injection (e.g., Depo Provera™), an intrauterine device, or
             an oral contraceptive taken continually within the past three months and which the
             subject agrees to continue using during the study or to adopt another birth control
             method, or a double-barrier method which consists of a combination of any two of the
             following: diaphragm, cervical cap, condom, or spermicide.

        Exclusion Criteria:

          1. Subject is &lt; 18 years of age and has a Body Mass Index (BMI) Z-Score below -1.5 (minus
             1.5)

          2. Subject has a history of any of the following gastrointestinal disorders:

               -  pancreatitis within 6 months prior to study entry;

               -  fibrosing colonopathy;

               -  distal ileal obstruction syndrome (DIOS) within 6 months prior to study entry;

               -  celiac disease;

               -  gastric bypass or partial/total gastrectomy;

               -  Crohn's disease;

               -  small bowel surgery (other than minor resection due to meconium ileus without
                  resulting in malabsorption syndrome).

               -  Any type of malignancy involving the digestive tract in the last 5 years.

          3. Subjects with diabetes mellitus, for which the study specific dietary requirements may
             not be appropriate.

          4. Subject has a history of other endocrine or respiratory (except mild asthma) medical
             illness non-related to CF, which might limit participation in or completion of the
             study.

          5. Subject has a history of any clinically significant neurological, cardiac, renal,
             hepatic (including Hepatitis B or C), hematologic or psychiatric disease or disorder,
             or any other uncontrolled medical illness (except cystic fibrosis) which might limit
             participation in or completion of the study.

          6. Subjects requiring concomitant treatment with any medication not allowed by the
             protocol or is expected to be needed.

          7. Subjects requiring Naso-gastric, G-tubes or J-tubes.

          8. Subject is currently participating in any other interventional clinical study or has
             taken any experimental drug within 30 days prior to Screening.

          9. Subject is known to be HIV-positive.

         10. Subject has a history of allergic reaction or significant sensitivity to pancreatin or
             inactive ingredients (excipients) of Creon® (DR/GR) or Creon IR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suntje Sander-Struckmeier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dětská nemocnice FN Brno, Centrum pro cystickou fibrozu</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika nemocí plicních a TBC</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Imre Kórház</name>
      <address>
        <city>Ajka</city>
        <zip>8400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenézy Gyula Kórház</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mór Oktató Kórház</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tüdőgyógyintézet Törökbálint</name>
      <address>
        <city>Törökbálint</city>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Karpacz S.A.</name>
      <address>
        <city>Karpacz</city>
        <zip>58-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny Im M Kopernika W Łodzi</name>
      <address>
        <city>Lodzi</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janusz Stankiewicz Sanatorium &quot;&quot;Cassia-Villa Medica</name>
      <address>
        <city>Rabka</city>
        <zip>34-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podkarpacki Ośrodek Pulmonologii i Alergologii</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-612</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ENEL-MED Szpital Centrum</name>
      <address>
        <city>Warszawa</city>
        <zip>01-195</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d ´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya, Hospital Civil, Secretaria de Endocrinologia</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío, Hospital de la Mujer</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fé Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exocrine Pancreatic Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Creon IR Low Dose</title>
          <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="P2">
          <title>Creon IR Medium Dose</title>
          <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="P3">
          <title>Creon IR High Dose</title>
          <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="P4">
          <title>Creon IR Maximum Dose</title>
          <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="P5">
          <title>Creon® (DR/GR)</title>
          <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Creon IR Low Dose</title>
          <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="B2">
          <title>Creon IR Medium Dose</title>
          <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="B3">
          <title>Creon IR High Dose</title>
          <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="B4">
          <title>Creon IR Maximum Dose</title>
          <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="B5">
          <title>Creon® (DR/GR)</title>
          <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="14"/>
            <count group_id="B6" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" spread="7.6"/>
                    <measurement group_id="B2" value="22.9" spread="8.5"/>
                    <measurement group_id="B3" value="22.0" spread="7.3"/>
                    <measurement group_id="B4" value="19.7" spread="8.4"/>
                    <measurement group_id="B5" value="22.6" spread="7.1"/>
                    <measurement group_id="B6" value="22.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coefficient of Fat Absorption (CFA)</title>
        <description>CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake</description>
        <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
        <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
        <group_list>
          <group group_id="O1">
            <title>Creon IR Low Dose</title>
            <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O2">
            <title>Creon IR Medium Dose</title>
            <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O3">
            <title>Creon IR High Dose</title>
            <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O4">
            <title>Creon IR Maximum Dose</title>
            <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O5">
            <title>Creon® (DR/GR)</title>
            <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Fat Absorption (CFA)</title>
          <description>CFA is calculated from fat intake and fat excretion, according to the formula: CFA (%) = 100 [fat intake - fat excretion] / fat intake</description>
          <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
          <units>percentage of fat intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="12.4"/>
                    <measurement group_id="O2" value="70.9" spread="13.9"/>
                    <measurement group_id="O3" value="71.8" spread="15.2"/>
                    <measurement group_id="O4" value="75.9" spread="9.2"/>
                    <measurement group_id="O5" value="92.3" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Coefficient of Nitrogen Absorption (CNA)</title>
        <description>CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)</description>
        <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
        <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
        <group_list>
          <group group_id="O1">
            <title>Creon IR Low Dose</title>
            <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O2">
            <title>Creon IR Medium Dose</title>
            <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O3">
            <title>Creon IR High Dose</title>
            <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O4">
            <title>Creon IR Maximum Dose</title>
            <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O5">
            <title>Creon® (DR/GR)</title>
            <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
          </group>
        </group_list>
        <measure>
          <title>Coefficient of Nitrogen Absorption (CNA)</title>
          <description>CNA is calculated from nitrogen intake and nitrogen excretion, according to the formula: CNA (%) = 100 [nitrogen intake - nitrogen excretion] / nitrogen intake)</description>
          <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
          <units>percentage of nitrogen intake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="10.0"/>
                    <measurement group_id="O2" value="73.2" spread="6.4"/>
                    <measurement group_id="O3" value="76.2" spread="8.1"/>
                    <measurement group_id="O4" value="79.9" spread="7.3"/>
                    <measurement group_id="O5" value="84.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Fat Content</title>
        <description>Total amount of fat excreted during the stool collection period in grams.</description>
        <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
        <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
        <group_list>
          <group group_id="O1">
            <title>Creon IR Low Dose</title>
            <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O2">
            <title>Creon IR Medium Dose</title>
            <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O3">
            <title>Creon IR High Dose</title>
            <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O4">
            <title>Creon IR Maximum Dose</title>
            <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O5">
            <title>Creon® (DR/GR)</title>
            <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Fat Content</title>
          <description>Total amount of fat excreted during the stool collection period in grams.</description>
          <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
          <units>gram per 72 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="37.5"/>
                    <measurement group_id="O2" value="87.1" spread="41.0"/>
                    <measurement group_id="O3" value="84.1" spread="44.9"/>
                    <measurement group_id="O4" value="73.0" spread="28.2"/>
                    <measurement group_id="O5" value="23.5" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Weight</title>
        <description>Total amount of stool weight during the collection period in grams</description>
        <time_frame>End of the 6 to 7 days double-blind treatment period</time_frame>
        <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
        <group_list>
          <group group_id="O1">
            <title>Creon IR Low Dose</title>
            <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O2">
            <title>Creon IR Medium Dose</title>
            <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O3">
            <title>Creon IR High Dose</title>
            <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O4">
            <title>Creon IR Maximum Dose</title>
            <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O5">
            <title>Creon® (DR/GR)</title>
            <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Weight</title>
          <description>Total amount of stool weight during the collection period in grams</description>
          <population>Full Analysis set. Four randomized subjects excluded because no post-baseline efficacy data (two non-completers and two subjects whose stools were mixed-up with each other at the analytical laboratory).</population>
          <units>gram per 72 hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="889.0" spread="294.2"/>
                    <measurement group_id="O2" value="905.3" spread="225.7"/>
                    <measurement group_id="O3" value="793.8" spread="279.8"/>
                    <measurement group_id="O4" value="755.7" spread="383.2"/>
                    <measurement group_id="O5" value="545.7" spread="256.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment Emergent Adverse Events</title>
        <description>Treatment emergent adverse events will be summarized per treatment group</description>
        <time_frame>From randomization to end of Double Blind period plus 1 day, i.e. up to 7/8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Creon IR Low Dose</title>
            <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O2">
            <title>Creon IR Medium Dose</title>
            <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O3">
            <title>Creon IR High Dose</title>
            <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O4">
            <title>Creon IR Maximum Dose</title>
            <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
          </group>
          <group group_id="O5">
            <title>Creon® (DR/GR)</title>
            <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Emergent Adverse Events</title>
          <description>Treatment emergent adverse events will be summarized per treatment group</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Creon IR Low Dose</title>
          <description>Creon IR 300 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="E2">
          <title>Creon IR Medium Dose</title>
          <description>Creon IR 1,200 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="E3">
          <title>Creon IR High Dose</title>
          <description>Creon IR 2,400 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="E4">
          <title>Creon IR Maximum Dose</title>
          <description>Creon IR 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon IR</description>
        </group>
        <group group_id="E5">
          <title>Creon® (DR/GR)</title>
          <description>Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
Creon® (DR/GR)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>infective pulmonary exacerbation due to CF</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>faeces soft</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suntje Sander-Struckmeier</name_or_title>
      <organization>Abbott</organization>
      <phone>+49 (0) 511 6750 3254</phone>
      <email>suntje.sander@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

